InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights 2024 Achievements and Outlines Key 2025 Milestones
January 13, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage neuropsychiatry company, summarized its 2024 accomplishments and detailed upcoming 2025 milestones. CEO Doug Drysdale highlighted advancements in its pipeline of tryptamine serotonin receptor agonists, including CYB003, a deuterated psilocin program for major depressive disorder (“MDD”), and CYB004, a deuterated dimethyltryptamine in intramuscular form for generalized anxiety disorder […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Lytham Partners Healthcare Summit
January 10, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company, announced that CEO Doug Drysdale will join a fireside chat at the virtual Lytham Partners 2025 Investor Healthcare Summit on Jan. 13. The live webcast begins at 11:30 a.m. ET, with an archived version accessible afterward on the company’s investor relations site. To view the […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights Promising Advances in Depression and Anxiety Treatment at ACNP Annual Meeting
December 10, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) presented compelling data from its clinical programs at the American College of Neuropsychopharmacology (“ACNP”) Annual Meeting, including 12-month efficacy results from its Phase 2 study of CYB003, a deuterated psilocin program for Major Depressive Disorder (“MDD”), which demonstrated a 100% response rate and 71% remission rate after two doses. […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Water Tower Research Fireside Chat
December 4, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options. The company has announced that its CEO Doug Drysdale and CMO Amir Inamdar, MBBS, DNB (Psych), FFPM will participate in the Water Tower Research Fireside Chat Series taking place […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports Sustained 12-Month Efficacy for CYB003 in Treating Major Depressive Disorder
November 18, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) shared promising 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated psilocin treatment for major depressive disorder (“MDD”). Participants receiving two 16 mg doses of CYB003, three weeks apart, achieved a 100% response rate and 71% remission rate at the 12-month mark, with an average […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present Key 12-Month Data and Phase 3 Program Insights for CYB003 in Upcoming Webcast
November 14, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) announced it will hold a conference call and webcast on Nov. 18, 2024, at 8 a.m. ET, led by CEO Doug Drysdale and CMO Amir Inamdar. The event will cover 12-month efficacy and safety results from its Phase 2 study of CYB003 for Major Depressive Disorder, along with an […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Begins Phase 3 Trials of CYB003 for Depression, Building on Promising Phase 2 Results
November 13, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) has initiated its Phase 3 PARADIGM program to evaluate the efficacy and safety of CYB003, an adjunctive treatment for Major Depressive Disorder (MDD). PARADIGM includes three pivotal studies: APPROACH, EMBRACE, and EXTEND, each aimed at examining CYB003’s potential to deliver rapid and durable relief from depressive symptoms. In Phase 2, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present Advancements in Mental Health Treatment at Milken Institute Summit
October 31, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will join a panel titled “The Next Frontier in Mental Health Research” at the 2024 Milken Institute Future of Health Summit in Washington, D.C., on November 13. Drysdale will discuss Cybin’s progress in developing breakthrough treatments for mental health conditions, including CYB003, a Phase […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Granted Patent for Lead Candidates in CYB005 Program
October 24, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that the United States Patent and Trademark Office has granted U.S. patent 12,122,741 for the composition of matter related to lead preclinical candidates in its CYB005 phenethylamines program. This patent supports Cybin’s development of non-hallucinogenic treatments for Central Nervous System (“CNS”) disorders. Cybin is focused on expanding its […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in Upcoming Water Tower Research Fireside Chat
October 3, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today announced participation in the Water Tower Research Fireside Chat Series on Tuesday, October 8, 2024, at 3 p.m. ET. Cybin CEO Doug Drysdale will join the fireside chat hosted by Robert Sassoon, Senior Research Analyst […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Strengthens Its Clinical Development Team
October 1, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today announced the appointment of talented and experienced industry leaders to its clinical and R&D team. The company welcomed Dr. Mirza Rahman, M.D., M.P.H., FACPM, as Senior Vice President, Patient Safety & Pharmacovigilance and Dr. Marcelo […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Chief Medical Officer to Participate in a Panel Discussion at Upcoming Summit
September 24, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today announced that it will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit to be held virtually on Thursday, September 26, 2024. The company’s Chief Medical Officer, Amir Inamdar, will be part […]
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Subsidiary Signs Agreement with Evofem Biosciences Inc. (OTCQB: EVFM) Involving Unique Endometriosis Diagnostic Test
September 20, 2024
Aditxt (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and its majority-owned subsidiary, Pearsanta Inc., have signed a market development collaboration agreement with Evofem Biosciences (OTCQB: EVFM), a women’s health company. According to the announcement, the agreement involves Pearsanta’s blood-based diagnostic test for endometriosis, which affects an estimated 190 million women globally. The […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports on Status of Key Clinical Milestones
September 20, 2024
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, has provided an update on corporate accomplishments and clinical milestones. According to the announcement, the company is planning to begin a pivotal CYB003 phase 3 study in major depressive disorder (“MDD”) […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Completes 38-for-1 Share Consolidation
September 19, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today announced that it has completed the previously announced consolidation of its issued and outstanding common shares. Trading of the common shares reflecting the consolidation commenced at the opening of trading on Thursday morning. According to […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
September 4, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options. The company today announced that its CEO, Doug Drysdale, will participate in a fireside chat and panel discussion at the H.C. Wainwright 26th Annual Global Investment Conference. The event will be held September 9-11, 2024, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Annual and Special Meeting of Shareholders, Share Consolidation
August 28, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is releasing the report of its annual and special meeting of shareholders. Held on Aug. 27, 2024, the meeting included 87 shareholders, attending in person or by proxy; those persons […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Holds Initial Breakthrough Therapy Meeting with FDA, Plans for CYB003 Phase 3 Trial
August 13, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, met with the U.S. Food and Drug Administration (“FDA”) to hold a Type B Initial Breakthrough Therapy Meeting. The meeting, which was held last week, was regarding the company’s plans […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases Q1 2025 Financial Results, Business Highlights
August 8, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today reported unaudited financial results for its first quarter of fiscal 2025 ended June 30, 2024 (“Q1 2025”) and provided recent business highlights. In the report, the company noted continued progress towards initiating its Phase 3 […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in a Fireside Chat at Upcoming Conference
August 7, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, today announced that its CEO, Doug Drysdale, will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024, at 2 p.m. ET. Mr. Drysdale’s fireside chat will be […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Sees “Swell” of Insider Investments, Upgrade in Ranking after Positive Year-End Report
July 8, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting “a swell” of insider purchases following the company’s year-end update; the report highlighted significant advancements that strengthened Cybin’s position in the development of next-generation psychedelic-based therapeutics. […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Releases FY Financial Report, Business Update
June 26, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting its audited financial results for the fiscal year ended March 31, 2024; the report also included a business overview. Highlights of the report include the company […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Featured Presenter at Upcoming H.C. Wainwright Neuro Perspectives Virtual Conference
June 20, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, will be spotlighted during an upcoming online fireside chat at the H.C. Wainwright Fifth Annual Neuro Perspectives Virtual Conference. According to the announcement, Cybin CEO Doug Drysdale will present during […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Strategic Appointment of Dr. Atul Mahableshwarkar
June 11, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options. The company today announced its appointment of Dr. Atul R. Mahableshwarkar M.D., DLFAPA, as its senior vice president, clinical development. Dr. Mahableshwarkar will lead the development of the CYB003 […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at Interdisciplinary Conference on Psychedelic Research 2024
May 29, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options. The company today announced that its Chief Medical Officer Amir Inamdar, MBBS, DNB (Psych), MFPM and Director, Clinical Development Ellen James, Ph.D. will participate at the Interdisciplinary Conference on […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO Slated to Present at Upcoming Alliance Global Partners Healthcare Company Showcase
May 14, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, will be participating in an upcoming virtual Alliance Global Partners Healthcare Company Showcase. The event is scheduled for May 21, 2024. According to the announcement, Cybin CEO Doug Drysdale will […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Issues Corporate Update, Eyes Runway for Upcoming Clinical Milestones
May 6, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options. The company has provided a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline. “With the prevalence and burden of mental health conditions at […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at the 27th Annual Milken Institute Global Conference
April 25, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, is announcing its participation at the 27th Annual Milken Institute Global Conference, set to take place May 5-8, 2024, at the Beverly Hilton in Los Angeles. According to the announcement, Doug Drysdale, Cybin CEO, will appear […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Update on Plan of Arrangement with Exopharm Limited
April 24, 2024
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved a previously announced plan of arrangement between Exopharm Limited and Tryp (the “parties”). The announcement confirmed […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Research Published in “Journal of Medicinal Chemistry”
April 18, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, is reporting that its research has been published in a prestigious biweekly, peer-reviewed publication. Titled “Synthesis and Structure-Activity Relationships of 2,5-dimethoxy-4-substituted phenethylamines and the discovery of CYB210010: A potent, orally […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Receives Notice of Patent Grant for CYB003 Breakthrough MDD Therapy Program
April 16, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, has received notification that the United States Patent and Trademark Office has granted a patent in support of its CYB003 program in Major Depressive Disorder (“MDD”). The patent covers claims […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) to Present at Bloom Burton & Co. Healthcare Conference
April 10, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, announced that its CEO Doug Drysdale will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference. The event is slated to take place April 16-17 in Toronto, Ontario. […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Upcoming Public Ventures Discovery Day
March 18, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, will be presenting at this week’s Public Ventures Discovery Day. The event is scheduled for March 19, 2024, in Dallas. During the event, Cybin CEO Doug Drysdale will participate in […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Initiates Phase 2 Study of CYB004 for Generalized Anxiety Disorder
March 15, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is reporting the initiation of a Phase 2 proof-of-concept study of CYB004, its proprietary deuterated dimethyltryptamine (“DMT”) molecule in development for the treatment of generalized anxiety disorder (“GAD”). The randomized, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports on Meeting with FDA to Review End of Phase 2 Study, Proposed Phase 3 Program
March 14, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, is reporting on its end-of-phase-2 meeting with the U.S. Food and Drug Administration (“FDA”). The meeting was regarding CYB003, the company’s deuterated psilocybin analog for the adjunctive treatment of major […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Executives Share CYB003 Program Update During Webcast
March 13, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, hosted a conference call and webcast this morning at 8:30 a.m. ET. According to the announcement, the company provided an update on CYB003, its proprietary deuterated psilocybin analog being developed […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Shareholders Approve Arrangement Agreement at Annual General and Special Meeting
March 13, 2024
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, announced that company shareholders approved an announced arrangement involving the company and Exopharm Limited CAN 163 765 991. Tryp securityholders approved the arrangement during the company’s annual […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Upcoming TD Cowen Health Care Conference
February 27, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be spotlighted at next month’s 44th annual TD Cowen Health Care Conference. The three-day event is scheduled for March 4–6, 2024, in Boston. During the conference, Cybin CEO Doug Drysdale […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Q3 Results, Recent Business Highlights
February 14, 2024
Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic treatment options, today announced unaudited financial results for its third quarter ended Dec. 31, 2023, and recent business highlights. “During the past three months, we have continued to make exciting progress […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Interim Order from BC Supreme Court, Plans Meeting of Securityholders
February 9, 2024
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has obtained an interim order of the Supreme Court of British Columbia in connection with the proposed arrangement between Tryp and Exopharm Limited ACN 163 765 991. […]